title: Effect of desmopressin acetate administration on primary hemostasis in Doberman Pinschers with type-1 von Willebrand disease as assessed by a point-of-care instrument.
abstract: OBJECTIVE
  To evaluate primary hemostasis following administration of desmopressin acetate (DDAVP) to Doberman Pinschers with type-1 von Willebrand disease (vWD).
  
  
  METHODS
  16 nonanemic Doberman Pinschers with type-1 vWD.
  
  
  METHODS
  Closure time (CT), defined as time required for occlusion of an aperture by a platelet plug assessed within the point-of-care instrument, plasma von Willebrand factor (vWF) concentration, and buccal mucosal bleeding time (BMBT) were determined before and 1 hour after administration of DDAVP (1 microg/kg, SC).
  
  
  RESULTS
  Baseline closure times measured with adenosine diphosphate ([ADP-CT], 108 to > 300 seconds; reference range, 52 to 86 seconds) and epinephrine ([EPI-CT], 285 to > 300 seconds; 97 to 225 seconds) as platelet agonists were prolonged in all dogs. Following DDAVP administration, ADP-CT (59 to 186 seconds) was significantly shortened from baseline, but there was no decrease in EPI-CT. Although mean plasma vWF concentration increased significantly after DDAVP administration, only 1 dog had an increase of > 35 U/dL. There was no correlation between increase in plasma vWF concentration and shortening of the ADP-CT. Baseline BMBT was prolonged in 12 of 14 dogs, with significant shortening of BMBT after DDAVP administration in 6 of 7 dogs. In vitro replacement of vWF-deficient plasma with plasma from an unaffected dog shortened the ADP-CT whereas in vitro addition of DDAVP had no effect.
  
  
  CONCLUSIONS
  Administration of DDAVP to Doberman Pinschers with type-1 vWD resulted in improved hemostatic function, as assessed by the point-of-care instrument and shortening of BMBT, despite minimal increase in plasma vWF concentration.
authors.affiliation: Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
authors.forename: Mary Beth
authors.initials: MB
authors.lastname: Callan
authors.forename: Urs
authors.initials: U
authors.lastname: Giger
mesh_terms: D000244:Adenosine Diphosphate / Q000378:metabolism; D000818:Animals; D001760:Bleeding Time / Q000662:veterinary; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology* / Q000627:therapeutic use; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D004837:Epinephrine / Q000378:metabolism; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D006490:Hemostatics / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count / Q000662:veterinary; D014842:von Willebrand Diseases / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*
chemical_list: D006490:Hemostatics; D000244:Adenosine Diphosphate; D003894:Deamino Arginine Vasopressin; D004837:Epinephrine